

1 ***Plasmodium falciparum* vacuolar pyrophosphatase 1 for ring stage development and its**
2 **transition to trophozoite**

3 Omobukola Solebo¹, Liqin Ling^{1,2}, Jing Zhou², Tian-Min Fu^{3,4}, Hangjun Ke^{1,*}

4 Running title: PfVP1 in *Plasmodium falciparum*

5 ¹Center for Molecular Parasitology, Department of Microbiology and Immunology, Drexel
6 University College of Medicine, Philadelphia, Pennsylvania, USA

7 ²Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, China

8 ³Department of Biological Chemistry and Pharmacology, The Ohio State University College of
9 Medicine, Columbus, OH 43210

10 ⁴The Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210

11 *Correspondence: hk84@drexel.edu

12

13

14

15

16

17

18

19

20

21 **Abstract**

22 The malaria parasite relies on anaerobic glycolysis for energy supply when growing inside
23 RBCs as its mitochondrion does not produce ATP. The ring stage lasts ~ 20 hours and is
24 traditionally thought to be metabolically quiescent. However, recent studies show that the ring
25 stage is active for several energy-costly processes including gene transcription/translation,
26 protein export, and movement inside the RBC. It has remained unclear if a low glycolytic flux
27 can meet the energy demand of the ring stage. Here we show that the metabolic by-product,
28 pyrophosphate, is a critical energy source for the development of the ring stage and its
29 transition to the trophozoite stage. During early phases of the asexual development, the parasite
30 utilizes PfVP1 (*Plasmodium falciparum* vacuolar pyrophosphatase 1), an ancient
31 pyrophosphate-driven proton pump, to pump protons across the parasite plasma membrane to
32 maintain the membrane potential and cytosolic pH. Conditional deletion of PfVP1 leads to
33 delayed ring stage development and a complete blockage of the ring-to-trophozoite transition,
34 which can be partially rescued by *Arabidopsis thaliana* vacuolar pyrophosphatase 1, but not by
35 the soluble pyrophosphatase from *Saccharomyces cerevisiae*. Proton-pumping
36 pyrophosphatases are absent in humans, which highlights the possibility of developing highly
37 selective VP1 inhibitors against the malaria parasite.

38

39

40

41

42

43

44 **Introduction**

45 Malaria is a threat to 40% of the world's population and claims nearly half a million lives each
46 year¹. In a human host, the malaria parasite grows exponentially in bloodstream RBCs, causing
47 all clinical symptoms including death in severe cases. In *Plasmodium falciparum*, the 48 h
48 Intraerythrocytic Development Cycle (IDC) can be divided into three major developmental
49 stages, including the ring, the trophozoite, and the schizont. These stages take about ~ 22h, ~
50 18h, and ~ 8h, respectively. Within the RBC, the parasite resides in a vacuole and is
51 surrounded by three membranes: parasite plasma membrane (PPM), the parasitophorous
52 vacuolar membrane (PVM), and the RBC membrane (RBCM). A major task of the ring stage
53 parasite is to export proteins to the host cell to increase its permeability and cytoadherence².
54 Over the ~ 22 h period, however, the parasite is not replicating DNA or expanding its biomass
55 significantly. After the RBCM has been permeabilized by the Plasmodium Surface Anion
56 Channel (PSAC)³, or New Permeability Pathways (NPPs)⁴, the trophozoite stage parasite starts
57 to grow rapidly, resulting in 16-32 progeny in the schizont stage.

58 It has been long recognized that the asexual stage parasites rely on anaerobic glycolysis for
59 ATP production^{5,6}. Per glucose consumed, the parasite makes 2 ATP and 2 lactate molecules,
60 with a minimal number of glucose-derived carbons fed into the tricarboxylic acid cycle (TCA)⁷.
61 Indeed, the parasite can tolerate deletions of many TCA cycle enzymes⁷ and some components
62 of the mitochondrial electron transport chain^{8,9}, implying that the mitochondrion is a negligible
63 source of ATP in blood stages. To overcome the energy constrain mediated by substrate-level
64 phosphorylation, the trophozoite stage parasite runs a high rate of glycolysis and consumes
65 glucose in a rate that is 100-times faster than normal RBCs¹⁰. Permeabilization of the RBCM in
66 this stage also facilitates lactate disposal to avoid a metabolic blockage of glycolysis. With an
67 intact RBCM, however, the ring stage is traditionally thought to be metabolically quiescent, with
68 a low-level of glycolysis being sufficient to meet the energy demand of this stage¹¹.

69 Recent studies, however, suggest that the ring stage parasite fulfills many energy-costly
70 processes over the 22 h period. Although the genome is not replicating at this stage, RNA
71 transcription and protein translation are active to form a ring stage specific proteome for all
72 necessary activities¹². The PTEX translocon catalyzes ATP hydrolysis to move hundreds of
73 parasite proteins to the RBC cytosol and membrane throughout the ring stage¹³. Rather than
74 being static, ring stage parasites undergo dynamic movement inside the RBC and display
75 morphological changes between the classical ring and a deformable ameboid-like structure¹⁴. In
76 addition, the ring stage parasite must spend energy to pump protons across the parasite plasma
77 membrane to maintain the plasma membrane potential ($\Delta\psi$). It has been shown that the ATP-
78 consuming V-type ATPase is the major proton pump in trophozoite stage parasites¹⁵. However,
79 no studies have been carried out to show how plasma membrane potential is maintained in ring
80 stages. RNA-seq data suggest that subunits of V-type ATPase are not highly transcribed until
81 the trophozoite stage¹⁶ (and **Figure S1**). Thus, it remains unknown how the ring stage parasite
82 pumps protons and meets its energy demand while running a low-level of glycolysis.

83 In this study, we discover that the ATP independent, proton pumping pyrophosphatase PfVP1
84 (*Plasmodium falciparum* vacuolar pyrophosphatase 1), is the major proton pump during ring
85 stage development. Proton-pumping pyrophosphatases, or H⁺-PPases, catalyze the hydrolysis
86 of inorganic pyrophosphate (PPi), a by-product of over 200 cellular reactions, while harnessing
87 the energy to pump protons across a biological membrane¹⁷. H⁺-PPase was first discovered in
88 the plant tonoplast and was also named vacuolar pyrophosphatase¹⁸. While H⁺-PPases are
89 absent in fungi and metazoans, it has been evolutionally conserved in bacteria, archaea, plants,
90 and many protozoans¹⁹. The *P. falciparum* genome encodes two types of H⁺-PPases, PfVP1
91 (PF3D7_1456800) and PfVP2 (PF3D7_1235200)²⁰. PfVP1 is potassium dependent and calcium
92 independent whereas PfVP2 is potassium independent and calcium dependent. RNA-seq data
93 suggest PfVP2 is barely transcribed¹⁶ (**Figure S1**), which is consistent with its non-essential role

94 in the asexual stages²¹. By contrast, PfVP1 is highly expressed throughout the IDC and exhibits
95 a peak expression in the ring stage¹⁶ (**Figure S1**). Our data reveal that the malaria parasite
96 employs PfVP1 to harness energy from pyrophosphate, an ancient energy source, to support
97 vital biological processes in the ring stage when ATP supply is relatively low.

98 **Results**

99 ***PfVP1 is mainly localized to the parasite plasma membrane (PPM)***

100 Previous attempts of localizing vacuolar pyrophosphatases in *P. falciparum* used polyclonal
101 antibodies raised against *Arabidopsis thaliana* vacuolar pyrophosphatase 1 (AVP1) in wildtype
102 parasites²², which were unable to differentiate PfVP1 from PfVP2. Therefore, to specifically
103 localize PfVP1, we utilized the CRISPR/Cas9 system^{23,24} to endogenously tag *pfvp1* with either
104 a triple hemagglutinin (3HA) tag or a monomeric fluorescent protein (mNeonGreen) in the 3D7-
105 PfVP2KO (knockout) parasite line²¹. Additionally, through gene editing of the endogenous copy,
106 the tagged *pfvp1* was placed under the control of the TetR-DOZI-aptamer system for conditional
107 expression²⁵ (**Figure S2**). Thus, two transgenic parasite lines were constructed, 3D7-PfVP2KO-
108 PfVP1-3HA^{apt} and 3D7-PfVP2KO-PfVP1-mNeonGreen^{apt}. We also cloned 3D7-PfVP2KO-
109 PfVP1-3HA^{apt} by limited dilution and obtained two pure parasite clones, B11 and G11, which
110 were phenotypically indistinguishable (B11 was used for this study). The parasite lines were
111 normally cultured in the presence of 250 nM anhydrotetracycline (aTc) to maintain PfVP1
112 expression.

113 The subcellular localization of PfVP1 was verified by immunofluorescence analysis (IFA),
114 immuno-electron microscopy (immuno-EM), and live fluorescence microscopy (**Figure 1**). In the
115 3D7-PfVP2KO-PfVP1-3HA^{apt} line, IFA revealed clear colocalization of PfVP1 and the PVM
116 marker, PfEXP2, throughout the 48 h IDC (**Figure 1A**). Since the PVM is permeable to
117 protons²⁶, the close proximity of PfVP1 to PfEXP2 suggests PfVP1 is localized on the PPM.

118 Further, immuno-EM studies with the HA tagged line showed localization of PfVP1 mainly to the
119 PPM (**Figure 1B**). Quantification of 65 random images revealed 90% of the gold particles were
120 localized to the PPM, ~ 2% of the gold particles were localized to nucleus/ER, and ~ 8% of the
121 gold particles were localized to the cytosol or cytosolic small membranous structures with
122 unknown identities (**Figure S3**). No gold particles were apparently localized on the food
123 vacuole. To further confirm this, we performed co-localization studies of PfVP1 and the food
124 vacuole using the food vacuole marker, PfPlasmepsin II²⁷. We were unable to find any parasites
125 in which PfVP1 and PfPlasmepsin II colocalized (**Figure S4**). Thus, PfVP1 did not coincide with
126 the food vacuole as previously thought²⁸. Finally, we used live microscopy to localize PfVP1 in
127 the 3D7-PfVP2KO-PfVP1-mNeonGreen^{apt} line. PfVP1 was clearly localized to the PPM in every
128 stage of the IDC, including the merozoite, the ring, the trophozoite, and the schizont stages
129 (**Figure 1C**). Together, we utilized three independent methods to show that PfVP1 is mainly
130 localized to the PPM.

131 In the 3D7-PfVP2KO-PfVP1-3HA^{apt} line, we revealed PfVP1 was also highly expressed by
132 Western blot (**Figure 1D**). A regular amount of total parasite lysate (~ 15 µg) contained an
133 abundant amount of PfVP1, from the monomeric form of 79 kDa to large, aggregated oligomers
134 that were not solubilized by 2% SDS. The aggregated forms agreed with the fact that PfVP1
135 contains 16 transmembrane helices and is highly insoluble.

136 ***Characterizing PfVP1 using the *Saccharomyces cerevisiae* heterologous system***

137 To confirm PfVP1 is a PPI-dependent proton pump, we expressed PfVP1 in *S. cerevisiae*. Since
138 the 1990s, this heterologous system²⁹ has been widely applied to study many VP1 orthologs
139 from plants and Archaea³⁰⁻³². *S. cerevisiae* does not have VP1 homologs and thus provides a
140 robust and clean system to study exogenous VP1 proteins²⁹. Importantly, isolated yeast
141 vacuolar vesicles incorporating recombinant VP1 are suitable for testing the pump's ability to

142 move protons from one side of the membrane to the other. The vesicles can also be used to
143 examine VP1's enzymatic activity. We transformed the yeast strain BJ5459^{33,34}, which was null
144 for the two major vacuolar proteases, PrA and PrB, with plasmids containing a copy of synthetic
145 codon optimized PfVP1, AVP1, or a blank control. VP1 proteins were N-terminally tagged with
146 the localization peptide of *Trypanosoma cruzi* VP1 (the first 28 amino acids) and GFP, which
147 facilitates VP1's localization to yeast vacuoles³⁵. Yeast expression of PfVP1 and AVP1 was
148 verified by fluorescence microscopy, which showed that the GFP signal appeared mainly on the
149 yeast vacuoles (**Figure S5**).

150

151 We followed the established protocols³⁶ to isolate yeast vesicles from these three lines
152 expressing PfVP1, AVP1, or the blank control (**Figure 2A**). In isolated yeast vesicles, a 9-
153 Amino-6-Chloro-2-Methoxyacridine (ACMA) fluorescence quenching assay was used to assess
154 the ability of VP1 to pump protons into their lumen (Materials and Methods). The compound's
155 fluorescence is quenched when a pH gradient forms across the vesicle membrane. The yeast
156 V-type ATPase, also present on the vesicles, was inhibited by Bafilomycin A1. Over time, PfVP1
157 possessing vesicles were able to reduce ACMA fluorescence (**Figure 2B**). The positive control
158 AVP1 expressing vesicles also quenched ACMA, as expected, whereas the negative control
159 vesicles bearing no H⁺-PPase exhibited little effect. When Nigericin was added (a proton
160 ionophore that abolishes transmembrane proton gradients), the quenched ACMA fluorescence
161 was restored to its original levels (**Figure 2B**). This verified that the yeast vesicles were intact
162 and PfVP1 and AVP1 expressing vesicles had accumulated protons inside. We also assessed
163 PfVP1's enzymatic activity by measuring free Pi released by PPI hydrolysis (Materials and
164 Methods). In comparison to the negative control vesicles, PfVP1 expressing vesicles produced
165 a net of 1.24 μ moles free Pi per mg of protein per h, similar to that produced by the AVP1
166 vesicles (1.14 μ moles/mg/h) (**Figure 2C**). Together, using the yeast heterologous expression
167 system, we confirmed that PfVP1 is a PPI hydrolyzing proton pump.

168 ***PfVP1 is essential for ring stage development***

169 To investigate PfVP1's essentiality during the 48h IDC, we set up knockdown studies and
170 examined parasite viability and morphology in the 3D7-PfVP2KO-PfVP1-3HA^{apt} line. We used
171 two approaches to remove aTc from cultures to initiate PfVP1 knockdown. In one approach, aTc
172 was removed from Percoll isolated schizonts. In the other, aTc was removed from synchronized
173 ring stage parasites. When aTc was removed from schizonts, the knockdown culture did not
174 display discernible changes in parasite morphology or parasitemia in the first IDC (**Figures 3A**).
175 This was likely because a prolonged time (~ 48 h) was needed to knock down greater than 95%
176 of the PfVP1 protein (**Figure S6A**). However, in the second IDC after aTc removal, the
177 knockdown parasites then showed drastic morphological changes (**Figures 3A**). Although
178 invasion was apparently unaffected in the absence of PfVP1 (**Figure S6B**), the parasites
179 struggled to progress through the ring stage and failed to become an early stage trophozoite in
180 the second IDC. From 72 to 96 h, while the parasites in aTc (+) medium progressed normally
181 from the ring to schizont stage, the size of the knockdown parasites barely increased. It
182 appeared that PfVP1 knockdown resulted in an extended ring stage as long as ~ 48 h. To better
183 understand the morphological changes in the 2nd IDC after aTc removal, we examined parasite
184 development every 4 h (**Figures 3B**). Again, PfVP1 knockdown caused delayed ring stage
185 development and a complete blockage of the ring to trophozoite transition. At the end of the 2nd
186 IDC, we noticed that the knockdown parasites had expanded the cytosol slightly in comparison
187 to parasites of earlier time-points and small hemozoin particles were also visible (**Figure 3B**).
188 However, none of the knockdown parasites showed the morphology of a normal early
189 trophozoite stage parasite. In the absence of PfVP1, the parasites were arrested in this state for
190 several days before lysing and was unable to finish the asexual cycle. Moreover, the blockage

191 of ring to trophozoite transition was also observed when the knockdown experiment was
192 initiated from ring stage parasites (**Figure 3C**).

193 To examine if the arrested parasites are viable, we added aTc back to the culture after aTc was
194 removed for 72, 84 and 96 h from schizonts. The arrested ring stage parasites were able to fully
195 progress if aTc was given back at 72 and 84 h post knockdown (data not shown), indicating that
196 they were viable. When aTc was added back at 96 h after knockdown, however, the arrested
197 parasites displayed poor growth in the next IDC. Although most of them were able to progress
198 to the trophozoite stage, many appeared sick-looking and lysed on the next day (**Figure S7**).
199 The total parasitemia only increased marginally in the aTc addback culture (**Figure S7**).
200 Altogether, this data clearly establish that PfVP1 is essential for ring stage development, and its
201 absence halts the maturation of the parasites at the late ring stage.

202 ***Phenotypic characterization of the PfVP1 knockdown parasites***

203 We next characterized the knockdown phenotypes in the 3D7-PfVP2KO-PfVP1-3HA^{apt} line. We
204 reasoned if PfVP1 was genuinely a PPI-dependent proton pump located on the PPM, changes
205 to cytosolic pH and PPI levels would be expected in the knockdown parasite. We used the
206 ratiometric pH sensitive dye 2',7'-Bis-(2-Carboxyethyl)-5-(and-6)-Carboxyfluorescein,
207 Acetoxymethyl Ester (BCECF-AM), to measure cytosolic pH following the established protocol¹⁹.
208 BCECF-AM is membrane permeable and is trapped inside the parasite cytosol after its ester
209 group is removed. We initially aimed to measure cytosolic pH at 48, 72 and 96 h after aTc
210 removal from schizonts; however, attempts to measure pH in ring stage parasites were
211 unsuccessful. Our experience agreed with the fact that BCECF-AM has only been reported to
212 measure cytosolic pH in trophozoite stage parasites^{19,37,38}, not in the ring stage. Nonetheless,
213 we successfully detected a decrease of cytosolic pH in the knockdown culture at 48 h post aTc
214 removal (**Figure 4A**). Next, we measured PPI levels in the knockdown cultures using a newly

215 developed PPI specific sensor (Materials and Methods). At 72, 84, and 96 h post aTc removal,
216 saponin-lysed pellets were collected, and soluble metabolites were extracted using a mild
217 process (Materials and Methods). In each sample, the concentrations of PPI and total parasite
218 protein were measured, and the total amount of PPI (nanomoles) was normalized to total protein
219 (mg). We observed an increase of PPI at 84 and 96 h after aTc removal (**Figure 4B**). Together,
220 these data not only reveal the mode of action of PfVP1 in *Plasmodium*, but also suggest that
221 when PfVP1 is knocked down, the cytosolic proton and PPI levels increase, likely preventing
222 parasite's transition from the ring to trophozoite stage.

223 We next employed a chemical-genetic approach to examine how the knockdown parasites
224 responded to antimalarials. Starting at ring stages, we washed out aTc and set up 72h SYBR
225 green assays with varying concentrations of aTc (10, 5, 1 and 0 nM). We used 10 nM as the
226 highest concentration since it was sufficient to support 100% parasite growth (data not shown).
227 Drug inhibition plots and EC₅₀ values obtained with parasites grown at 10 or 5 nM aTc were
228 similar to those found with wild type parasites. However, the PfVP1 knockdown parasites
229 became hypersensitive to all antimalarials tested when aTc concentrations were reduced to 1 or
230 0 nM (**Figure 4C**). This data indicated that when PfVP1 was knocked down, the parasite was so
231 ill that it became sensitive to extremely low concentrations of all antimalarials tested. Inhibitors
232 against PfVP1, if available, would therefore be expected to have synergy with many
233 antimalarials. Of note, efforts to develop H⁺-PPase inhibitors have already begun by others³⁹.

234 ***Complementation of the knockdown parasite line with yIPP1 or AVP1***

235 In *A. thaliana*, AVP1 acidifies the plant vacuole in conjunction with V-type ATPase. The proton
236 pumping activity of AVP1 is not as critical as the PPI hydrolysis activity since a loss-of-function
237 of AVP1 was rescued by the yeast inorganic pyrophosphatase (yIPP1), the soluble
238 pyrophosphatase from *S. cerevisiae*⁴⁰. yIPP1 has the sole function of PPI removal, with no

239 energy saving or proton pumping activity. Therefore, the proton pumping activity and PPI
240 hydrolysis activity of AVP1 can be de-coupled. To test if this is also true for PfVP1, we
241 performed a second round of transfection to complement the knockdown parasite with a copy of
242 Myc-tagged yIPP1, AVP1 or wildtype PfVP1.

243 To this end, we made a new knockdown line in the D10 wildtype background, resulting D10-
244 PfVP1-3HA^{apt} line. We transfected D10-PfVP1-3HA^{apt} parasites with plasmids bearing hDHFR
245 for selection⁴¹ and 3Myc-tagged yIPP1, AVP1 or PfVP1 (Materials and Methods). Western blots
246 showed that all Myc tagged copies were expressed independent of aTc, while the endogenous
247 HA tagged PfVP1 was knocked down when aTc was removed (**Figure 5A**). As expected,
248 fluorescence microscopy showed PfVP1 or AVP1 was localized to the PPM whereas yIPP1 was
249 in the cytosol (**Figure 5B**). When aTc was removed from schizonts for 96 h, the knockdown
250 parasite complemented with PfVP1-3Myc displayed normal growth like the aTc (+) control,
251 indicating that the episomal PfVP1 fully complemented the endogenous copy (**Figure 5C**).
252 AVP1 complementation displayed a moderate rescue with two thirds of the parasites reaching
253 the same morphology as control parasites (late trophozoite), and one third progressing to a
254 smaller size (early trophozoite). In contrast, yIPP1 was unable to restore parasite growth when
255 the endogenous PfVP1 was knocked down. A quantification of various parasite morphologies in
256 all conditions is shown in **Figure 5D**. Altogether, this data indicates 1) both PfVP1's PPI
257 hydrolysis and proton pumping activities are essential for parasite survival, and 2) although not
258 a 100% functional replacement, the homologous plant VP1 is able to complement VP1-deficient
259 *Plasmodium* parasites.

260 **Structure-guided mutagenesis studies of PfVP1**

261 To further understand the mode of action of PfVP1, we conducted structure-guided mutagenesis
262 studies in *P. falciparum*. All VP1 orthologs have 15-17 transmembrane helices with a molecular

263 mass of 70-81 kDa¹⁹. The crystal structure of *Vigna radiata* (mung bean) VP1 (VrVP1) was
264 resolved in 2012¹⁷. At the primary sequence level, PfVP1 is highly similar to VrVP1 (49%
265 identity and 66% similarity). The transmembrane (TM) helices are well conserved between
266 PfVP1 and VrVP1, although the inter-domain loops display noticeable differences (**Figure 6A**).
267 VrVP1 contains longer loops between the first three TMs. Based on the crystal structure, we
268 computationally modeled the structure of PfVP1; the model showed a high degree of
269 conservation to VrVP1 with deviations in some loop regions (**Figure 6B**). The substrate binding
270 and hydrolyzing site of the modeled PfVP1 also mimics that of VrVP1¹⁷. At this site, all the
271 conserved residues including 8 aspartates and 1 lysine are positioned around the substrate
272 analog, the magnesium imidodiphosphate (MgIDP) (**Figure 6C**). The proton transfer pathway
273 formed by TMs 5, 6, 11, 12 and 16 also appears to be structurally conserved (**Figure 6D**).
274 Based on these structural analyses, we chose to do alanine replacement mutagenesis of two
275 putative substrate binding residues (D236, D461) and two residues that appear to be in the
276 proton transfer channel and exit gate (D247, L697). Since *Plasmodium* is haploid and direct
277 mutagenesis of essential residues would be lethal, we performed these mutagenesis studies in
278 the D10-PfVP1-3HA^{apt} line by episomal expression of mutated alleles (Materials and Methods).
279 The effect of mutant PfVP1 on parasite viability was assessed upon knockdown of the
280 endogenous copy by aTc removal. Fluorescence microscopy showed all mutant PfVP1 proteins
281 were expressed and localized to the PPM (**Figure S8A**). When the endogenous HA tagged
282 PfVP1 was knocked down by aTc removal for 96 h, all Myc tagged PfVP1 mutant alleles were
283 still expressed (**Figure S8B**).
284 The mutant PfVP1 alleles had differing abilities to rescue the knockdown phenotype (**Figure**
285 **6E**). As a control, the episomal wildtype PfVP1 copy fully rescued the knockdown parasites
286 grown in aTc (-) medium. PfVP1 alleles with D236A and D247A mutations were unable to
287 rescue, indicating these mutations abolished the pump's functions. The PfVP1/D461A mutation

288 had partial rescuing ability, but most D461A expressing parasites were unable to progress to the
289 trophozoite stage. These results largely agreed with the results obtained with equivalent
290 mutations in VrVP1⁴². In contrast, PfVP1 differed from VrVP1 at mutation of L697A. When this
291 residue in VrVP1 was mutated (L749A), the pump has lost proton pumping activity, although the
292 PPI hydrolysis activity was largely remained⁴³. However, the PfVP1/L697A allele had both PPI
293 hydrolysis and proton pumping activities to fully rescue the knockdown culture. Since L697 is
294 located at the proton exit gate, our results indicate that PfVP1 may have some structural
295 variation from VrVP1 at least in this location. A quantification of the rescuing ability of the
296 various mutant PfVP1 alleles is shown in **Figure S8C**.

297 To explore the enzymatic and proton pumping activities of each mutant PfVP1 protein, we
298 utilized the yeast heterologous expression system as described in **Figure 2**. We individually
299 purified yeast vesicles bearing different codon optimized PfVP1 mutant alleles from the BJ5459
300 strain. Fluorescence microscopy showed all modified PfVP1 proteins were expressed and
301 localized to the yeast vacuole (**Figure S8D**). The enzymatic assays revealed that all mutant
302 PfVP1s, except for the L697A mutation, lacked PPI hydrolysis activity (**Figure 6F**). Likewise,
303 only PfVP1/L697A showed proton pumping activity in the ACMA quenching assay (**Figure 6G**).
304 Altogether, using homology modeling and yeast and parasite expression systems, we find that
305 the substrate binding site and proton transfer pathway of PfVP1 appear to be well conserved,
306 although the proton exit gate of PfVP1 may differ from that of the plant VP1.

307 **Discussion**

308 Our study has revealed that PfVP1 is highly expressed and mainly localized to the parasite
309 plasma membrane (**Figure 1**). Using the yeast heterologous expression system, we
310 demonstrated that PfVP1 is a PPI dependent proton pump (**Figure 2**). Our genetic data
311 uncovered the essential role of PfVP1 in early phases of the IDC, including the ring stage and

312 the ring to trophozoite transition (**Figures 3**). Conditional deletion of PfVP1 also resulted in the
313 accumulation of protons and PPI in the parasite (**Figures 4**). Overall, our data indicate that the
314 malaria parasite utilizes the ATP-independent proton pump PfVP1 to harness energy from
315 pyrophosphate, a metabolic by-product, to establish the parasite plasma membrane potential
316 ($\Delta\psi$) in the ring stage.

317 While the IDCs of different malaria parasites vary between 24-72 h, the ring stage is invariably
318 the longest period. In *P. falciparum*, the duration of the ring stage (~ 22 h) combined with the
319 transition stage from the ring to trophozoite (~2-4 h) is half of the entire IDC¹⁴. Inside the RBC,
320 the ring stage parasite moves, changes its shape¹⁴, and is busy exporting hundreds of proteins
321 to the host cell². Moreover, the ring stage is less susceptible to many antimalarial drugs and is
322 the only stage that displays artemisinin resistance⁵⁰. During the transition stage from the ring to
323 trophozoite, the parasite also exhibits pronounced changes¹⁴, including a reduction in the
324 parasite diameter, formation of several small hemozoin foci, and a transient echinocytosis of the
325 host cell (RBC membrane distortion). Despite the significance of these early phases of parasite
326 development, little is known about their cellular bioenergetics.

327 Earlier studies have shown that the ring stage parasite performs glycolysis at a much lower rate
328 compared to that of the trophozoite stage¹¹. Traditionally, a low-level of glycolysis is thought to
329 be sufficient to support ring stage development. However, our study has revealed that the
330 metabolic by-product PPI serves as a critical energy source during the early phases of the IDC.
331 The free energy of PPI hydrolysis under physiological conditions is estimated to be -28.9
332 kJ/mol⁴³, which is close to that of ATP hydrolysis (-30.5 kJ/mol). Evolutionarily, early life forms
333 on earth used PPI as the energy source before ATP emerged⁴⁴. The early divergent malaria
334 parasite has evolutionarily reserved the ability to use PPI as a critical energy source, especially
335 at the time when the ATP level is low. During the IDC, the malaria parasite's energy supply
336 depends on inefficient ATP production via anaerobic glycolysis as the parasite's mitochondrion

337 is not performing oxidative phosphorylation. Therefore, PPI becomes a significant energy
338 supplement to the ring stage parasite where glycolysis runs at a lower rate. Future studies will
339 focus on quantifications of ATP and PPI throughout the IDC to understand their energetic
340 contributions to the malaria parasite.

341 Unlike many other eukaryotes, malaria parasites generate the plasma membrane potential ($\Delta\psi$)
342 through the transport of protons rather than sodium ions⁴⁵. The proton gradient across the
343 plasma membrane is also used by the parasite to perform secondary active transport to move
344 ions, nutrients, or waste products into or out of the cell⁴⁶. It has been long recognized that the
345 malaria parasite possesses two different types of proton pumps, the single subunit PPI-
346 dependent H⁺-PPases^{20,22} and the much faster ATP-dependent multi-subunit V-type ATPase¹⁹.
347 Inhibition of the V-type ATPase by Bafilomycin A1 for 10-12 min causes a rapid drop of cytosolic
348 pH from ~ 7.3 to ~ 6.8 in trophozoite stage parasites¹⁹. Therefore, the much slower proton
349 pumps, PfVP1 and PfVP2, were thought to be insignificant or “marginal” to the parasite⁴⁶.
350 Alternatively, other studies have hypothesized that PfVP1 and/or PfVP2 would be critical to the
351 parasite when energy demand is high in trophozoite stage parasites²⁰. In contrast to those
352 earlier views, our results have now recognized the significance of PfVP1 for ring stage
353 development (PfVP2 is dispensable for asexual development²¹). Our data suggest that by using
354 PfVP1 to fulfill proton pumping across the PPM, the ring stage parasite can divert ATP to other
355 energy costly processes such as protein export. Therefore, for the first time, we have shown
356 that PfVP1 is the major proton pump in *Plasmodium falciparum* during the ring stage
357 development.

358 It is interesting to note that the ortholog VP1 protein in *Toxoplasma gondii* (TgVP1) displays
359 different subcellular localization and function. TgVP1 is mainly localized to acidocalcisomes and
360 the plant-like vacuole (PLV)^{47,48} and despite phenotypic alterations, a complete knockout of
361 TgVP1 is tolerated by the parasite⁴⁶. In *P. falciparum*, however, the large-scale mutagenesis

362 survey was unable to disrupt the PfVP1 gene⁴⁹. We have shown here that PfVP1 is essential for
363 the ring stage development. Hence, the conserved VP1 protein has seemingly adapted to
364 perform different functions even within the Apicomplexa phylum, to which *Toxoplasma* and
365 *Plasmodium* belong to. Unlike blood stage malaria parasites, *Toxoplasma gondii* has a much
366 more robust mitochondrion that is a significant ATP producer⁵⁰. On the other hand, our study
367 has not ruled out the possible localization of PfVP1 to acidocalcisomes in malaria parasites. In
368 contrast to *T. gondii* where acidocalcisomes are more abundant, the presence of these
369 organelles in *Plasmodium* remains obscure. Except for merozoites⁵¹, the classical
370 acidocalcisomes have not been firmly reported in other asexual stage parasites. Further
371 investigation is needed to clarify if acidocalcisomes are present in malaria parasites and if
372 PfVP1 is present on them.

373 In summary, our data suggest that the malaria parasite utilizes PfVP1 to harness energy from
374 PPi to establish the plasma membrane potential, extrude cytosolic protons, and maintain an
375 energy homeostasis. The essential nature of PfVP1 combined with the absence of any
376 orthologs in humans has also highlighted it as a potential antimalarial drug target. A drug target
377 in the ring stage is highly desired to the drug development pipeline, inhibitors of which could be
378 partnered with many other antimalarials that kill metabolically more active stages. A combination
379 therapy targeting both young and mature malaria parasites can then ensure all parasite forms
380 are dispatched. Although at early stages, efforts of developing inhibitors against H⁺-PPases
381 including PfVP1 have already begun³⁹.

382

383 **Materials and Methods**

384 1, Plasmid construction for studies in *P. falciparum* and *S. cerevisiae* was described in
385 Supplementary Information.

386 2, Parasite culture, transfection, and knockdown studies

387 The 3D7-PfVP2KO (PfVP2 knockout) line was generated previously²¹. We used RPMI-1640
388 media supplemented with Albumax I (0.5%) to culture *P. falciparum* parasites in human O⁺
389 RBCs as previously described^{41,52}. We transfected *P. falciparum* ring stage parasites (~ 5%
390 parasitemia) either with linearized or circular plasmid (~ 50 µg) using a BioRad electroporator.
391 Post electroporation, parasite cultures were maintained in proper drug selections, e.g.,
392 blasticidin (2.5 µg/mL, InvivoGen), WR99210 (5 nM, a kind gift from Jacobs Pharmaceutical),
393 and anhydrotetracycline (aTc) (250 nM, Fisher Scientific). Parasite synchronization was
394 performed with several rounds of alanine/HEPES (0.5M/10 mM) treatment. For knockdown
395 studies, synchronized parasites were washed thrice with 1xPBS to remove aTc and diluted in
396 fresh blood (1:10) to receive aTc (+) or (-) media.

397 3, Yeast culture, yeast lines and transformation

398 The *S. cerevisiae* strain BJ5459 was kindly supplied by Dr. Katrina Cooper from Rowan
399 University³⁴, which was originally created by³³. This strain (*MATa*, *his3Δ200*, *can1*, *ura3–52*,
400 *leu2Δ1*, *lys2–801*, *trp1-289*, *pep4Δ::HIS3*, *prb1Δ1.6R*) lacks yeast vacuolar proteases PrA
401 (proteinase A) and PrB (proteinase B). Yeast cultures were maintained at 30°C either in YPD or
402 Uracil drop-out medium. YPD medium contains 1% yeast extract (BP1422-500, Fisher
403 Scientific), 2% peptone (20-260, Genesee Scientific), and 4% dextrose. Ura drop-out medium
404 contains uracil minus complete supplement mixture (1004-010, Sunrise Science) and dropout
405 base powder (1650-250, Sunrise Science). The latter has yeast nitrogen base (1.7 g/L),
406 ammonium sulfate (5 g/L) and dextrose (20 g/L). Ura drop-out solid medium contains extra 2%

407 agar. Yeast transformation was carried out using the Frozen-EZ Yeast Transformation II Kit
408 (T2001, Zymo Research), according to manufacturer's protocols.

409 4, Immunofluorescence analysis (IFA) and immuno-electron microscopy

410 IFA was carried out as previously described^{41,52}. Immuno-EM was performed at the Molecular
411 Microbiology Imaging Facility at Washington University in St. Louis, MO. We used the following
412 primary antibodies and dilutions: the HA probe (mouse, sc-7392, Santa Cruz Biotechnology;
413 1:300), the Myc probe (rabbit, 2278S, Cell signaling; 1:300), PExp2 (rabbit, a kind gift from Dr.
414 James Burns, Drexel University; 1:500), and PfPlasmepsin II (rabbit, Bei Resources, NIAID/NIH;
415 1:1000). We used fluorescently labeled secondary antibodies from Life Technologies
416 (ThermoFisher Scientific) (anti-mouse or anti-rabbit, 1:300) or goat anti-mouse 18 nm colloidal
417 gold-conjugated secondary antibody (Jackson ImmunoResearch Laboratories), as described
418 previously⁵². Other details can be found⁵².

419 5, Western blot

420 Infected RBCs were lysed with 0.05% Saponin/PBS supplemented with 1x protease inhibitor
421 cocktail (Apexbio Technology LLC) and protein was extracted with 2%SDS/62 mM Tris-HCl (pH
422 6.8) as previously described^{41,52}. After protein transfer, the blot was stained with 0.1% Ponceau
423 S/5% acetic acid for 5 min, de-stained by several PBS washes, and blocked with 5% non-fat
424 milk/PBS. We used the following primary antibody dilutions: the HA probe (1:10,000), the Myc
425 probe (1:8,000), and PExp2 (1:10,000). We used HRP conjugated goat anti-mouse secondary
426 antibody (A16078, ThermoFisher Scientific) at 1:10,000 or goat anti-rabbit HRP-conjugated
427 secondary antibody (31460, ThermoFisher Scientific) at 1:10,000. Other steps followed the
428 standard BioRad Western protocols. For all Western samples, protein concentration was
429 determined using the detergent tolerant Pierce™ BCA Protein Assay Kit (23227, ThermoFisher)
430 according to the manufacturer's protocols.

431 6, pH measurement using BCECF-AM (2',7'-Bis-(2-Carboxyethyl)-5-(and-6)-Carboxyfluorescein,
432 Acetoxymethyl Ester)

433 We measured the pH of saponin permeabilized parasitized RBCs using the pH-sensitive
434 fluorescent dye (BCECF-AM) according to published protocols¹⁵. Details can be found in
435 Supplementary Information.

436 7, PPi extraction and measurement

437 Soluble metabolites were extracted from saponin treated parasites by four rounds of
438 freezing/thawing and mild sonication. PPi was measured using a PPi fluorogenic sensor from
439 Abcam (ab179836). The chemical identity of this sensor was not released by the manufacturer.
440 Details can be found in Supplementary Information.

441 8, SYBR Green Assays

442 We performed SYBR green assays as previously published⁵². Compounds used in this study
443 included Bafilomycin A1 (NC1351384, Cayman Chemical), chloroquine (AC455240250, Fisher
444 Scientific), atovaquone (A7986, MilliporeSigma), and artemisinin (a kind gift from Dr. Jianping
445 Song at Guangzhou University of Chinese Medicine, China). In brief, drugs were serially diluted
446 (3-fold) in 96 well plates in regular medium. Parasites from aTc plus culture (0.5% ring at 4%
447 hematocrit) were washed several times with PBS and resuspended in various concentrations of
448 aTc (20, 10, 2, or 0 nM) and incubated with diluted drugs, yielding final concentrations of aTc at
449 10, 5, 1, and 0 nM. Data was analyzed by GraphPad Prism6.

450 9, Yeast vesicle isolation

451 We followed published protocols to purify yeast vesicles expressing various VP1 proteins^{29,36}.
452 Details can be found in Supplementary Information.

453 10, ACMA pH Quenching Assay

454 We measured proton pumping activities of VP1 in isolated yeast vesicles using the ACMA
455 Fluorescence Quenching Assay³⁶. ACMA stands for 9-amino-6-chloro-2-methoxyacridine
456 (A1324, ThermoFisher Scientific). For each measurement in the spectrofluorometer (Hitachi F-
457 7000), 30 µg of vesicles were added to the 1 mL of transport buffer (100 mM KCl, 50 mM NaCl,
458 and 20 mM HEPES) in the presence of 1 µM of ACMA, 3 mM MgSO₄, 1 mM of Na₂PPi and 1
459 µM of Bafilomycin A1 (inhibitor of the yeast V-type ATPase). The reaction was monitored for 15
460 minutes to observe any decrease in fluorescence (excitation 410 nm, emission 490 nm).
461 Afterwards, 10 µM of Nigericin is added to the solution and monitored for 3 min to see if the
462 fluorescence could be restored.

463

464 11, Pyrophosphatase activity

465 The release of Pi by pyrophosphatase activity of VP1 proteins in isolated yeast vesicles was
466 measured using the P_iPer™ Phosphatase Assay Kit (P22061, ThermoFisher Scientific),
467 according to manufacturer's protocols. The Pi derived from PPi hydrolysis is coupled to three
468 enzymatic reactions to convert a nonfluorescent compound (amplex red) to fluorescent
469 resorufin. Fluorescence was detected by Tecan infinite 200 pro at 565 nm with excitation at 530
470 nm. A Pi standard curve was generated to determine Pi concentrations in the samples.

471

472

473

474 **Figure Legend**

475 **Figure 1. PfVP1 is mainly localized to the parasite plasma membrane**

476 A, Immunofluorescence assay of Pf3D7VP2KO-VP1-3HA. DAPI stains the nuclei. Green,
477 PfVP1-3HA. Red, PfEXP2. Note an ameboid ring stage parasite in the first row. R, ring. T,
478 trophozoite. S, schizont. Scale bar, 5 μ m. B, Immunoelectron microscopy. RBCM, RBC
479 membrane. PVM, parasitophorous vacuolar membrane. PPM, parasite plasma membrane.
480 Scale bars, 200 nm. C, Live imaging of Pf3D7VP2KO-VP1-mNeonGreen. M, merozoite. R, ring.
481 T, trophozoite. S, schizont. Scale bar, 5 μ m. D, Live imaging of Percoll enriched Pf3D7VP2KO-
482 VP1-mNeonGreen parasites. Scale bar, 10 μ m. E, Western blot showing PfVP1-3HA
483 expression. PfExp2 is the loading control.

484 **Figure 2. PfVP1 is a PPI hydrolyzing proton pump**

485 A, A general schematic of purifying yeast vesicles bearing VP1 proteins from *Saccharomyces*
486 *cerevisiae*. Yeast cells were treated with Zymolyase to remove the cell wall, lysed by Dounce,
487 and applied to a ficoll gradient (16% and 8%). After ultracentrifugation, yeast vesicles were
488 collected from the top. B, ACMA quenching assay. The ACMA's fluorescence signal was
489 recorded after the yeast vesicles were added with the substrate, Na₂PPI. Data shown are the
490 representative of five individual experiments. C, Pyrophosphatase activity. The background
491 activity from the negative control (NC) vesicles was subtracted from all measurements. This
492 experiment was repeated three times with (n=3) technical replicates.

493 **Figure 3. PfVP1 is essential for the ring to trophozoite transition**

494 A, Knockdown experiment starting at the schizont stage. B, Parasite morphological changes
495 throughout the time course. Green box, aTc (+). Red box, aTc (-). C, Knockdown experiment
496 starting at the ring stage. A-C, images were Giemsa-stained thin blood smears. Bars, 5 μ m. B-

497 C, White arrows indicate hemozoin particles. These experiments were repeated more than five
498 times (A, C) or two times (B).

499 **Figure 4. Phenotypic analysis of the PfVP1 knockdown parasite**

500 A, pH measurement in the knockdown parasite after aTc removal for 48 h from the schizont
501 stage. B, PPI measurement in the knockdown parasite. In A-B, error bars indicate variations of
502 $n=3$ measurements in each condition; statistical analysis was done by Student t-test. *, $p < 0.05$.
503 **, $p < 0.01$. ***, $p < 0.001$. C, Sensitivity to antimalarials measured by SYBR green assays.
504 EC_{50} values were only retrievable from cultures grown in 10 or 5 nM aTc. Bafilomycin A1, 8.1 vs
505 7.5 nM. Chloroquine, 6.3 vs 6.4 nM. Artemisinin, 7.3 vs 10.2 nM. Atovaquone, 0.1 vs 0.15 nM.
506 This experiment was repeated three times.

507 **Figure 5. The dual functionality of PfVP1 is required for parasite survival**

508 A, Western blot of complemented proteins. PfExp2 serves as a loading control. B,
509 Immunofluorescence analysis (IFA). The complemented lines were probed with anti-Myc and a
510 fluorescent secondary antibody. Scale bar, 5 μ m. C, Morphologies of complemented parasite
511 lines at 96 h after aTc removal. This experiment was repeated three times. D, Quantification of
512 parasite morphologies in C. The percentage of different parasite morphological stages was
513 determined by counting 1000 infected RBCs in each condition. R, ring. ET, early trophozoite.
514 LT, late trophozoite. S, schizont. This experiment was repeated two times. A-D, KD means
515 knockdown.

516 **Figure 6. Structure guided mutagenesis analysis of PfVP1**

517 A, 2D schematic of PfVP1 and VrVP1 containing 16 transmembrane helices (TMs). In each
518 monomer, TMs of 5, 6, 11, 12, 15, 16 (darker) form the inner circle whereas the rest 10 TMs
519 (lighter) form the outer circle. Protons are pumped from the cytosolic side to the luminal side. B.

520 Structure of PfVP1 (green) overlaid with the crystal structure of *Vigna radiate* VP1 (VrVP1,
521 pink). The PfVP1 structure was predicted using RoseTTaFold. C. Substrate binding site of
522 PfVP1. The side chains of substrate binding amino acids were highlighted in sticks. Magnesium
523 ions were shown in magenta spheres. IDP stands for imidodiphosphate, which was used to co-
524 crystalize VrVP1¹⁷. Boxed residues will be mutated. D. Side view of the inner circle formed by
525 TM5, TM6, TM11, TM12 and TM16. The proton transfer pathway is located at the lower part of
526 the inner circle. Residues subjected to mutagenesis are indicated. E, Parasite morphologies of
527 mutated PfVP1 lines at 96 h after aTc removal from the schizont stage. Giemsa-stained smears
528 were shown. This experiment was repeated three times. F, Pyrophosphatase activity. The
529 background activity of negative control (NC) yeast vesicles was subtracted from all
530 measurements. This experiment was repeated three times (n=3). G, Proton pumping activity of
531 mutant PfVP1 alleles. Data shown are the representative of 3-5 experiments in each yeast line.

532 **Acknowledgements**

533 We thank members of the Ke lab, Swati Dass, Neeta Shadija, and Dr. Maruthi Mulaka, for
534 technical assistance. We thank members of the Dr. Akhil Vaidya's lab at Drexel University for
535 constructive discussions and Dr. Michael Mather, Ian Lamb, and Swaksha Rachuri for editing
536 the manuscript. We thank Dr. Kendal Hirschi's lab (Baylor College of Medicine) and Dr. Katrina
537 Cooper's lab (Rowan University) for providing yeast plasmids and strains. We thank Dr. James
538 Burn (Drexel University), Dr. Daniel Goldberg (Washington University St Louis), and Dr. Joshua
539 Beck (Iowa State University) for providing antibodies and plasmids. We thank Dr. Jacquin Niles
540 (Massachusetts Institute of Technology) and Dr. Sean Prigge (Johns Hopkins University) for
541 providing the knockdown tools. We thank Dr. Wandy Beatty (Washington University St Louis) for
542 performing immune-EM studies. This work was supported by a Career Transition Award from
543 NIH/NIAID (K22AI127702) and a R21 grant from NIH/NIAID (1R21AI156735) to Dr. Hangjun Ke.

544 **Author contributions**

545 O.S., L.L., and H.K. performed all experiments. T.M.F generated the modeled PfVP1 structures.

546 H.K. and J.Z. designed all experiments. H.K. and O.S. wrote the manuscript, which was

547 reviewed and edited by all other authors.

548 **Competing interests**

549 The authors declare no competing interests.

550 **Data availability**

551 All data generated in this study have been included in the manuscript and the supplementary

552 information.

553

554

555

556

557

558

559

560

561

562

563 References

- 564 1 WHO. World Malaria Report. (2020).
- 565 2 Beck, J. R. & Ho, C. M. Transport mechanisms at the malaria parasite-host cell
566 interface. *PLoS Pathog* **17**, e1009394, doi:10.1371/journal.ppat.1009394 (2021).
- 567 3 Desai, S. A., Bezrukov, S. M. & Zimmerberg, J. A voltage-dependent channel involved in
568 nutrient uptake by red blood cells infected with the malaria parasite. *Nature* **406**, 1001-
569 1005, doi:10.1038/35023000 (2000).
- 570 4 Ginsburg, H., Krugliak, M., Eidelman, O. & Cabantchik, Z. I. New permeability pathways
571 induced in membranes of Plasmodium falciparum infected erythrocytes. *Mol Biochem*
572 *Parasitol* **8**, 177-190, doi:10.1016/0166-6851(83)90008-7 (1983).
- 573 5 Speck, J. F., Evans, E. A. Jr. The Biochemistry of the Malaria Parasite II. Glycolysis in
574 Cell-Free Preparations of the Malaria Parasite. *J Biol Chem* **159** (1945).
- 575 6 Sherman, I. W. Biochemistry of Plasmodium (malarial parasites). *Microbiol Rev* **43**, 453-
576 495, doi:10.1128/mr.43.4.453-495.1979 (1979).
- 577 7 Ke, H. *et al.* Genetic investigation of tricarboxylic acid metabolism during the
578 Plasmodium falciparum life cycle. *Cell Rep* **11**, 164-174,
579 doi:10.1016/j.celrep.2015.03.011 (2015).
- 580 8 Ke, H. *et al.* Mitochondrial type II NADH dehydrogenase of Plasmodium falciparum
581 (PfNDH2) is dispensable in the asexual blood stages. *PLoS One* **14**, e0214023,
582 doi:10.1371/journal.pone.0214023 (2019).
- 583 9 Sturm, A., Mollard, V., Cozijnsen, A., Goodman, C. D. & McFadden, G. I. Mitochondrial
584 ATP synthase is dispensable in blood-stage Plasmodium berghei rodent malaria but
585 essential in the mosquito phase. *Proc Natl Acad Sci U S A* **112**, 10216-10223,
586 doi:10.1073/pnas.1423959112 (2015).
- 587 10 Kirk, K. Membrane transport in the malaria-infected erythrocyte. *Physiol Rev* **81**, 495-
588 537, doi:10.1152/physrev.2001.81.2.495 (2001).
- 589 11 Pfaller, M. A., Krogstad, D. J., Parquette, A. R. & Nguyen-Dinh, P. Plasmodium
590 falciparum: stage-specific lactate production in synchronized cultures. *Exp Parasitol* **54**,
591 391-396, doi:10.1016/0014-4894(82)90048-0 (1982).
- 592 12 Bozdech, Z. *et al.* The transcriptome of the intraerythrocytic developmental cycle of
593 Plasmodium falciparum. *PLoS Biol* **1**, E5, doi:10.1371/journal.pbio.0000005 (2003).
- 594 13 Ho, C. M. *et al.* Malaria parasite translocon structure and mechanism of effector export.
595 *Nature* **561**, 70-75, doi:10.1038/s41586-018-0469-4 (2018).
- 596 14 Gruring, C. *et al.* Development and host cell modifications of Plasmodium falciparum
597 blood stages in four dimensions. *Nat Commun* **2**, 165, doi:10.1038/ncomms1169 (2011).
- 598 15 Saliba, K. J. & Kirk, K. pH regulation in the intracellular malaria parasite, Plasmodium
599 falciparum. H(+) extrusion via a V-type H(+)-ATPase. *J Biol Chem* **274**, 33213-33219,
600 doi:10.1074/jbc.274.47.33213 (1999).
- 601 16 Bartfai, R. *et al.* H2A.Z demarcates intergenic regions of the plasmodium falciparum
602 epigenome that are dynamically marked by H3K9ac and H3K4me3. *PLoS Pathog* **6**,
603 e1001223, doi:10.1371/journal.ppat.1001223 (2010).
- 604 17 Lin, S. M. *et al.* Crystal structure of a membrane-embedded H⁺-translocating
605 pyrophosphatase. *Nature* **484**, 399-403, doi:10.1038/nature10963 (2012).
- 606 18 Takeshige, K., Tazawa, M. & Hager, A. Characterization of the H Translocating
607 Adenosine Triphosphatase and Pyrophosphatase of Vacuolar Membranes Isolated by
608 Means of a Perfusion Technique from Chara corallina. *Plant Physiol* **86**, 1168-1173,
609 doi:10.1104/pp.86.4.1168 (1988).

- 610 19 Holmes, A. O. M., Kalli, A. C. & Goldman, A. The Function of Membrane Integral
611 Pyrophosphatases From Whole Organism to Single Molecule. *Front Mol Biosci* **6**, 132,
612 doi:10.3389/fmolb.2019.00132 (2019).
- 613 20 McIntosh, M. T., Drozdowicz, Y. M., Laroia, K., Rea, P. A. & Vaidya, A. B. Two classes
614 of plant-like vacuolar-type H(+)-pyrophosphatases in malaria parasites. *Mol Biochem*
615 *Parasitol* **114**, 183-195, doi:10.1016/s0166-6851(01)00251-1 (2001).
- 616 21 Ganesan, S. M. *et al.* Yeast dihydroorotate dehydrogenase as a new selectable marker
617 for Plasmodium falciparum transfection. *Mol Biochem Parasitol* **177**, 29-34,
618 doi:10.1016/j.molbiopara.2011.01.004 (2011).
- 619 22 Luo, S., Marchesini, N., Moreno, S. N. & Docampo, R. A plant-like vacuolar H(+)-
620 pyrophosphatase in Plasmodium falciparum. *FEBS Lett* **460**, 217-220,
621 doi:10.1016/s0014-5793(99)01353-8 (1999).
- 622 23 Ghorbal, M. *et al.* Genome editing in the human malaria parasite Plasmodium falciparum
623 using the CRISPR-Cas9 system. *Nat Biotechnol* **32**, 819-821, doi:10.1038/nbt.2925
624 (2014).
- 625 24 Wagner, J. C., Platt, R. J., Goldfless, S. J., Zhang, F. & Niles, J. C. Efficient CRISPR-
626 Cas9-mediated genome editing in Plasmodium falciparum. *Nat Methods* **11**, 915-918,
627 doi:10.1038/nmeth.3063 (2014).
- 628 25 Ganesan, S. M., Falla, A., Goldfless, S. J., Nasamu, A. S. & Niles, J. C. Synthetic RNA-
629 protein modules integrated with native translation mechanisms to control gene
630 expression in malaria parasites. *Nat Commun* **7**, 10727, doi:10.1038/ncomms10727
631 (2016).
- 632 26 Desai, S. A. & Rosenberg, R. L. Pore size of the malaria parasite's nutrient channel.
633 *Proc Natl Acad Sci U S A* **94**, 2045-2049, doi:10.1073/pnas.94.5.2045 (1997).
- 634 27 Klemba, M., Beatty, W., Gluzman, I. & Goldberg, D. E. Trafficking of plasmepsin II to the
635 food vacuole of the malaria parasite Plasmodium falciparum. *J Cell Biol* **164**, 47-56,
636 doi:10.1083/jcb200307147 (2004).
- 637 28 Saliba, K. J. *et al.* Acidification of the malaria parasite's digestive vacuole by a H+
638 ATPase and a H+-pyrophosphatase. *J Biol Chem* **278**, 5605-5612,
639 doi:10.1074/jbc.M208648200 (2003).
- 640 29 Kim, E. J., Zhen, R. G. & Rea, P. A. Heterologous expression of plant vacuolar
641 pyrophosphatase in yeast demonstrates sufficiency of the substrate-binding subunit for
642 proton transport. *Proc Natl Acad Sci U S A* **91**, 6128-6132, doi:10.1073/pnas.91.13.6128
643 (1994).
- 644 30 Kim, E. J., Zhen, R. G. & Rea, P. A. Site-directed mutagenesis of vacuolar H(+)-
645 pyrophosphatase. Necessity of Cys634 for inhibition by maleimides but not catalysis. *J*
646 *Biol Chem* **270**, 2630-2635, doi:10.1074/jbc.270.6.2630 (1995).
- 647 31 Drozdowicz, Y. M. *et al.* A thermostable vacuolar-type membrane pyrophosphatase from
648 the archaeon Pyrobaculum aerophilum: implications for the origins of pyrophosphate-
649 energized pumps. *FEBS Lett* **460**, 505-512, doi:10.1016/s0014-5793(99)01404-0 (1999).
- 650 32 Van, R. C. *et al.* Role of transmembrane segment 5 of the plant vacuolar H+
651 pyrophosphatase. *Biochim Biophys Acta* **1709**, 84-94, doi:10.1016/j.bbabi.2005.05.011
652 (2005).
- 653 33 Jones, E. W., Zubenko, G. S. & Parker, R. R. PEP4 gene function is required for
654 expression of several vacuolar hydrolases in Saccharomyces cerevisiae. *Genetics* **102**,
655 665-677 (1982).
- 656 34 Willis, S. D., Hanley, S. E., Beishke, T., Tati, P. D. & Cooper, K. F. Ubiquitin-
657 proteasome-mediated cyclin C degradation promotes cell survival following nitrogen
658 starvation. *Mol Biol Cell* **31**, 1015-1031, doi:10.1091/mbc.E19-11-0622 (2020).
- 659 35 Perez-Castineira, J. R., Hernandez, A., Drake, R. & Serrano, A. A plant proton-pumping
660 inorganic pyrophosphatase functionally complements the vacuolar ATPase transport

- 661 activity and confers bafilomycin resistance in yeast. *Biochem J* **437**, 269-278,
662 doi:10.1042/BJ20110447 (2011).
- 663 36 Scholz-Starke, J. *et al.* The flip side of the Arabidopsis type I proton-pumping
664 pyrophosphatase (AVP1): Using a transmembrane H(+) gradient to synthesize
665 pyrophosphate. *J Biol Chem* **294**, 1290-1299, doi:10.1074/jbc.RA118.006315 (2019).
- 666 37 Hayashi, M. *et al.* Vacuolar H(+)-ATPase localized in plasma membranes of malaria
667 parasite cells, *Plasmodium falciparum*, is involved in regional acidification of parasitized
668 erythrocytes. *J Biol Chem* **275**, 34353-34358, doi:10.1074/jbc.M003323200 (2000).
- 669 38 Tang, T. *et al.* Inhibitory Mechanisms of DHA/CQ on pH and Iron Homeostasis of
670 Erythrocytic Stage Growth of *Plasmodium Falciparum*. *Molecules* **24**,
671 doi:10.3390/molecules24101941 (2019).
- 672 39 Johansson, N. G. *et al.* Discovery of Membrane-Bound Pyrophosphatase Inhibitors
673 Derived from an Isoxazole Fragment. *ACS Med Chem Lett* **11**, 605-610,
674 doi:10.1021/acsmchemlett.9b00537 (2020).
- 675 40 Ferjani, A. *et al.* Keep an eye on PPI: the vacuolar-type H⁺-pyrophosphatase regulates
676 postgerminative development in Arabidopsis. *Plant Cell* **23**, 2895-2908,
677 doi:10.1105/tpc.111.085415 (2011).
- 678 41 Ke, H., Dass, S., Morrissey, J. M., Mather, M. W. & Vaidya, A. B. The mitochondrial
679 ribosomal protein L13 is critical for the structural and functional integrity of the
680 mitochondrion in *Plasmodium falciparum*. *J Biol Chem* **293**, 8128-8137,
681 doi:10.1074/jbc.RA118.002552 (2018).
- 682 42 Asaoka, M., Segami, S. & Maeshima, M. Identification of the critical residues for the
683 function of vacuolar H(+)-pyrophosphatase by mutational analysis based on the 3D
684 structure. *J Biochem* **156**, 333-344, doi:10.1093/jb/mvu046 (2014).
- 685 43 Frey, P. A. & Arabshahi, A. Standard free energy change for the hydrolysis of the alpha,
686 beta-phosphoanhydride bridge in ATP. *Biochemistry* **34**, 11307-11310,
687 doi:10.1021/bi00036a001 (1995).
- 688 44 Baykov, A. A., Malinen, A. M., Luoto, H. H. & Lahti, R. Pyrophosphate-fueled Na⁺ and
689 H⁺ transport in prokaryotes. *Microbiol Mol Biol Rev* **77**, 267-276,
690 doi:10.1128/MMBR.00003-13 (2013).
- 691 45 Allen, R. J. & Kirk, K. The membrane potential of the intraerythrocytic malaria parasite
692 *Plasmodium falciparum*. *J Biol Chem* **279**, 11264-11272, doi:10.1074/jbc.M311110200
693 (2004).
- 694 46 Ginsburg, H. Abundant proton pumping in *Plasmodium falciparum*, but why? *Trends*
695 *Parasitol* **18**, 483-486, doi:10.1016/s1471-4922(02)02350-4 (2002).
- 696 47 Miranda, K. *et al.* Characterization of a novel organelle in *Toxoplasma gondii* with similar
697 composition and function to the plant vacuole. *Mol Microbiol* **76**, 1358-1375,
698 doi:10.1111/j.1365-2958.2010.07165.x (2010).
- 699 48 Liu, J. *et al.* A vacuolar-H(+)-pyrophosphatase (TgVP1) is required for microneme
700 secretion, host cell invasion, and extracellular survival of *Toxoplasma gondii*. *Mol*
701 *Microbiol* **93**, 698-712, doi:10.1111/mmi.12685 (2014).
- 702 49 Zhang, M. *et al.* Uncovering the essential genes of the human malaria parasite
703 *Plasmodium falciparum* by saturation mutagenesis. *Science* **360**,
704 doi:10.1126/science.aap7847 (2018).
- 705 50 Huet, D., Rajendran, E., van Dooren, G. G. & Lourido, S. Identification of cryptic subunits
706 from an apicomplexan ATP synthase. *Elife* **7**, doi:10.7554/eLife.38097 (2018).
- 707 51 Ruiz, F. A., Luo, S., Moreno, S. N. & Docampo, R. Polyphosphate content and fine
708 structure of acidocalcisomes of *Plasmodium falciparum*. *Microsc Microanal* **10**, 563-567,
709 doi:10.1017/S1431927604040875 (2004).

710 52 Ling, L. *et al.* Genetic ablation of the mitoribosome in the malaria parasite *Plasmodium*
711 *falciparum* sensitizes it to antimalarials that target mitochondrial functions. *J Biol Chem*
712 **295**, 7235-7248, doi:10.1074/jbc.RA120.012646 (2020).

713

714




Fig 1. PfVP1 is mainly localized to the parasite plasma membrane




Figure 2. PfVP1 is a PPI hydrolyzing proton pump




Fig 3. PfVFP1 is essential for the ring to trophozoite transition




Fig 4. Phenotypic characterization of the PfVP1 knockdown parasite




Fig 5. The dual functionality of PfVFP1 is required for parasite survival




Fig 6. Structure guided mutagenesis analysis of PfVP1